We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab—Reply

Sabine Tejpar, MD, PhD; Wendy De Roock, MD, PhD; Derek Jonker, MD
JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.88.
Text Size: A A A
Published online


In Reply: We agree with Dr Shitara and colleagues that the RASCAL II study did not show the same association between p.G13D KRAS mutations and worse prognosis1 as our analysis did. Unlike RASCAL II, which did not report the prognostic effect of the various KRAS mutations specifically in the metastatic setting, our data set was limited to this stage and specifically to chemotherapy refractory patients. In the PETACC-3 trial, no significant differences in prognostic value between the various types of KRAS mutations after univariate or multivariate survival models were observed.2 We agree that there were small numbers of patients with p.G13D-mutated tumors in the CO.17 data set, but a strict analysis of prognostic effect (as opposed to predictive effect) can only be performed on patients who received best supportive care alone, so a mixed comparison of some treated patients with all patients who received best supportive care would not properly address this issue but rather add additional confounders.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




February 9, 2011
Chen Mao, MD; Jin-Ling Tang, MD, PHD
JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.86.
February 9, 2011
Eeonora Zaccarelli, MD; Silverio Tomao, MD; Giovanni Codacci-Pisanelli, MD
JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.87.
February 9, 2011
Kohei Shitara, MD; Tomoya Yokota, MD; Kei Muro, MD
JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.85.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.